Regado Biosciences, Inc. continues to expand its patent portfolio by announcing issuance of a new patent for its product candidates, the REG1 AND REG2 Anticoagulation Systems

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced issuance of another key patent related to their proprietary technology. This new patent includes coverage for RB007, the modulator or active control component of Regado’s innovative product candidates, the REG1 and REG2 anticoagulation systems. The allowed claims in U.S. Patent No. 7,723,315 broadly cover modulators that are capable of binding to certain blood coagulation Factor IX/IXa inhibiting aptamers and include both composition of matter and methods of use claims. The term for this patent extends to April 2025..